6533b860fe1ef96bd12c3215

RESEARCH PRODUCT

Long-term cost-effectiveness of cognitive behavioral therapy versus psychodynamic therapy in social anxiety disorder.

Wolfgang HillerHans-helmut KönigAlexander KonnopkaBernhard StraussJuergen HoyerFalk LeichsenringJoerg WiltinkManfred E. BeutelEric LeibingUlrike WillutzkiUlrich StangierNina EggerSimone SalzerStephan Herpertz

subject

AdultMaleCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisTime03 medical and health sciencesIndirect costs0302 clinical medicineWillingness to paymedicineHumanshealth care economics and organizationsPsychodynamic psychotherapyCost–benefit analysisCognitive Behavioral TherapySocial anxietyPhobia Social3. Good health030227 psychiatryCognitive behavioral therapyPsychiatry and Mental healthClinical PsychologyTreatment OutcomeCognitive therapyFemalePsychologyPsychotherapy Psychodynamic030217 neurology & neurosurgeryClinical psychology

description

Background To determine the cost-effectiveness of cognitive behavioral therapy (CBT) versus psychodynamic therapy (PDT) in the treatment of social anxiety disorder after a follow-up of 30 months from a societal perspective. Methods This analysis was conducted alongside the multicenter SOPHO-NET trial; adults with a primary diagnosis of social anxiety disorder received CBT (n = 209) or PDT (n = 207). Data on health care utilization and productivity loss were collected at baseline, after 6 months (posttreatment), and three further follow-ups to calculate direct and indirect costs. Anxiety-free days (AFDs) calculated based on remission and response were used as measure of effect. The incremental cost-effectiveness ratio (ICER) was determined. Net benefit regressions, adjusted for comorbidities and baseline differences, were applied to derive cost-effectiveness acceptability curves. Results In the descriptive analysis, the unadjusted ICER favored CBT over PDT and the adjusted analysis showed that CBT's cost-effectiveness relative to PDT depends on the willingness to pay (WTP) per AFD. As baseline costs differed substantially the unadjusted estimates might be deceptive. If additional WTPs for CBT of €0, €10, and €30 were assumed, the probability of CBT being cost-effective relative to PDT was 65, 83, and 96%. Direct costs increased compared to baseline across groups, whereas indirect costs did not change significantly. Results were sensitive to considered costs. Conclusions If the society is willing to pay ≥€30 per additional AFD, CBT can be considered cost-effective, relative to PDT, with certainty. To further increase the cost-effectiveness more knowledge regarding predictors of treatment outcome seems essential.

10.1002/da.22540https://pubmed.ncbi.nlm.nih.gov/27428816